Targeted immunotherapy tested for Tough-to-Treat lymphoma
NCT ID NCT03990961
Summary
This study tested whether the immunotherapy drug pembrolizumab could help adults with a specific type of aggressive lymphoma that had returned or not responded to prior treatments. It focused on patients whose lymphoma cells had a particular genetic change (PD-L1 alteration). The trial was small and ended early, aiming to see if the drug could shrink tumors and control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.